Management of CML-blast crisis.

TitleManagement of CML-blast crisis.
Publication TypeJournal Article
Year of Publication2016
AuthorsHehlmann R, Saußele S, Voskanyan A, Silver RT
JournalBest Pract Res Clin Haematol
Date Published2016 Sep
KeywordsAllografts, Blast Crisis, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mutation, Prognosis, Protein Kinase Inhibitors, Stem Cell Transplantation

Tyrosine kinase inhibitors (TKI) have moderately improved survival in BC, but a median survival of less than 1 year is still unsatisfactory. This article reviews the various tests required for diagnosis of BC, features at diagnosis, treatment modalities (intensive chemotherapy, TKI, Allo-SCT and a selection of investigational agents), options of prevention and predictors of progression. The best prognosis is observed in patients that achieve a 2nd CP. Allo-SCT probably further improves prognosis of patients in 2nd CP. The choice of TKI should be directed by the mutation profile of the patient. BC can be prevented. A careful analysis of risk factors for progression may help. Current treatment options are combined in a concluding strategy for the management of BC.

Alternate JournalBest Pract Res Clin Haematol
PubMed ID27839570

Richard T. Silver MD Myeloproliferative Neoplasms Center 525 East 70th St., Starr Pavillion, 3rd Floor New York, NY 10021